Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Single Injection of REGN475/SAR164877 in Treatment of Vertebral Fracture Pain
- Conditions
- Back Pain
- Interventions
- Drug: REGN475/SAR164877Drug: Placebo (for REGN475/SAR164877)
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT01001715
- Locations
- 🇺🇸
Sanofi-Aventis Investigational Site Number 840017, Sacramento, California, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840026, New York, New York, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840013, Boynton Beach, Florida, United States
Single Injection of REGN475/SAR164877 in the Treatment of Chronic Pancreatitis Pain
- Conditions
- Abdominal Pain Upper
- Interventions
- Drug: Placebo (for REGN475/SAR164877)Drug: REGN475/SAR164877
- First Posted Date
- 2009-10-27
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT01001923
- Locations
- 🇺🇸
Sanofi-Aventis Investigational Site Number 840043, Dallas, Texas, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840003, Monterey, California, United States
🇺🇸Sanofi-Aventis Investigational Site Number 840052, Winston Salem, North Carolina, United States
A Study to Evaluate the Safety and Efficacy of Subcutaneously Administered REGN475(SAR164877) in Patients With Sciatic Pain
- First Posted Date
- 2009-10-07
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 159
- Registration Number
- NCT00991172
- Locations
- 🇺🇸
Regeneron Investigational Site, San Antonio, Texas, United States
🇺🇸Regeneron Invesitgational Site, West Jordan, Utah, United States
Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular ("Wet") Age-related Macular Degeneration (AMD)
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 323
- Registration Number
- NCT00964795
PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)
- First Posted Date
- 2009-08-13
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 248
- Registration Number
- NCT00958438
A Study of the Safety and Efficacy of REGN475(SAR164877) in Patients With Osteoarthritis of the Knee
- First Posted Date
- 2009-07-23
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 200
- Registration Number
- NCT00944892
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
- Conditions
- Macular Edema Secondary to Central Retinal Vein Occlusion
- Interventions
- Biological: VEGF Trap-Eye 2.0mgDrug: Sham
- First Posted Date
- 2009-07-21
- Last Posted Date
- 2013-05-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 189
- Registration Number
- NCT00943072
A Multiple-Ascending-Dose Study of the Safety and Tolerability of REGN421(SAR153192) in Patients With Advanced Solid Malignancies
- Conditions
- Advanced Solid Malignancies
- Interventions
- Drug: REGN421(SAR153192)
- First Posted Date
- 2009-03-30
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 83
- Registration Number
- NCT00871559
Study Utilizing Rilonacept in Gout Exacerbations
- Conditions
- Acute Gout Flare
- Interventions
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 225
- Registration Number
- NCT00855920
A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects
- Conditions
- Healthy
- Interventions
- Biological: REGN475 (SAR164877)
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2012-05-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 56
- Registration Number
- NCT00856310